IDH-mutant gliomas evade immune cell surveillance by reducing the immune-related cellular content and function of effector immune cells, downregulating NKG2D ligand expression, and overproducing 2-HG to inhibit complement pathways and T cell responses to interfere with immune surveillance and affect TME. This evidence concerns the gene KLRK1 and central nervous system cancer.